PHYS-STROKE Trial: Neuronal Autoantibody Associations with 6-Month Stroke Outcomes

200 stroke patients from the multicenter PHYS-STROKE trial were tested for 40 neuronal autoantibodies at baseline and up to six months post-stroke. The dataset, authored by Charlotte Pietrock and last updated in March 2026, includes associations between antibody seropositivity and neuropsychological and motor outcomes. Results indicate baseline seropositivity was linked to worse depression scores and poorer subjective mobility at six months.

Use Cases

• Modeling the association between specific autoantibodies like anti-NMDAR and subjective health ratings based on trial results.
• Analyzing the temporal dynamics of cell-based versus tissue-based antibody seroreactivity over a six-month period.
• Investigating prognostic factors for depression and motor function outcomes in stroke patients based on baseline biomarker status.

Strengths

• Data from a multicenter, randomized-controlled trial (PHYS-STROKE) with 200 enrolled patients.
• Longitudinal measurements of 40 neuronal autoantibodies at four timepoints over six months.
• Analysis includes multiple outcome measures such as depression scores, subjective mobility, and walking speed.

Limitations

• The dataset is small at 185.0 KB, indicating limited scope and sample size.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

Charlotte Pietrock via the PHYS-STROKE trial (NCT01953549).

Collection Method

Serum samples from stroke patients were tested for autoantibodies; outcomes were assessed using generalized estimating equation and multiple linear regression models.

Time Range

Measurements taken from baseline (5–45 days post-stroke) to six months post-stroke.

Freshness

Last updated 2026-03-18 06:55:38

Geography

Multicenter trial; specific geography is not stated.